|
KMID : 0985420200420040218
|
|
Laboratory Medicine and Quality Assurance
2020 Volume.42 No. 4 p.218 ~ p.223
|
|
|
Diagnostic Significance of the Ratio of Plasma CYFRA 21-1 Autoantibody Immune Complex to Free CYFRA 21-1 in Patients with Colon Cancer
|
|
Choi Hong-Woo
Kim Hey-Jin
Oh Ae-Chin
Lee Jin-Kyung
Hong Young-Jun
|
|
|
Abstract
|
|
|
Background: The use of plasma autoantibodies associated with cancer as tumor biomarkers has been studied for several decades. We investigated the diagnostic significance of the ratio of CYFRA 21-1-anti-CYFRA 21-1 autoantibody immune complex (CIC), an autoantibody-binding form of CYFRA 21-1, to free CYFRA 21-1 in patients with colon cancer.
Methods: Overall, 50 patients with colon cancer and 120 healthy control subjects were included. Plasma CIC and CYFRA 21-1 levels were measured using a 9G DNA chip (Biometrix Technology Inc., Korea), and the CIC/CYFRA 21-1 ratios were calculated. Data were compared using the Student t-test or Mann-Whitney U-test. P-values <0.05 were considered to indicate statistical significance. We performed receiver operating characteristic curve analysis to determine the optimal CIC/CYFRA 21-1 cutoff ratio for detecting colon cancer.
Results: The CIC/CYFRA 21-1 ratio was significantly higher in the colon cancer group than in the healthy control group (mean±standard deviation, 1.81±0.75 vs. 1.23±0.37; P <0.001). The optimal cutoff ratio of CIC/CYFRA 21-1 for detecting colon cancer was 1.40 (area under curve [AUC], 0.749; 95% confidence interval, 0.658?0.839; P <0.001), with a sensitivity of 68.0% and specificity of 74.2%. The CIC/CYFRA 21-1 ratio showed higher AUC, sensitivity, and specificity than CYFRA 21-1 or CIC alone.
Conclusions: The plasma CIC/CYFRA 21-1 ratio can be a useful tumor marker in colon cancer.
|
|
|
KEYWORD
|
|
|
CYFRA 21-1, CIC, Autoantibody immune complex, Colon neoplasms
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|